drugset / Trial / NCT03614923

Etokimab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

NCT03614923

Phase 2 Completed 105 enrolled AnaptysBio, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

A study to evaluate the safety and efficacy of multiple doses of etokimab in adults with chronic rhinosinusitis with nasal polyps.

Timeline

Start
2018-11-29
Primary completion
2020-09-02
Completion
2020-10-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Etokimab Monoclonal antibody 150 mg Subcutaneous
Background Mometasone furoate Other / unclassified 200 ug Intranasal
Background Mometasone furoate Other / unclassified 400 ug Intranasal